Prof Andrew Coats (Monash University, AU & University of Warwick, UK) offers a summary on new targets that are being explored to improve contractility. Prof Coats discusses the importance of the GALACTIC-HF trial and omecamtiv mecarbil for patients with chronic HFrEF.

Recorded remotely form Melbourne, 2020. 

Recording Editor: Michael Knight
Editor: Mirjam Boros